This most likely reflects that in most cases of AML, KIT is not critically involved in sustaining abnormal proliferation, unlike BCR-ABL, which is pathogenetic in CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.